Hormone pellets, and the evidence nobody ranking for them will show you

What is hormone pellet therapy?

Hormone pellet therapy is a delivery route for hormone therapy: compressed pellets of estradiol or testosterone implanted under the skin, where they erode across 3 to 6 months. A clinician numbs a patch of skin over the upper buttock or hip, makes a small incision, and pushes the pellets into the fat layer with a trocar, after which hormone releases continuously as the pellet dissolves. Pellet names the route and bioidentical names the molecule, so the two words answer different questions: FDA-approved bioidentical estradiol exists in patch, gel, pill and vaginal form, and an FDA-approved estradiol pellet does not exist at all.

Every estradiol pellet and every testosterone pellet for women sold in the United States is compounded, which means it has not been through FDA review for safety, effectiveness or manufacturing quality. The category argument, and which telehealth platforms use compounded formularies, is on our bioidentical HRT guide.

What has the FDA actually approved?

Drugs@FDA contains 3 products whose dosage form is PELLET. Two are discontinued drugs with no relationship to hormone therapy. 1 is marketed: TESTOPEL, application ANDA 080911, marketed by Endo, originally approved 1972-07-13. The application number matters. An ANDA is the abbreviated pathway used for generics. It establishes equivalence to an already approved drug, and it requires no new registration trial.

The label limitation is the sentence that does the most work on this page. Age-related, or late-onset, hypogonadism describes most of the men who are sold pellets. The FDA-approved product says its own safety and efficacy in that group have not been established.

For estradiol the position is simpler. A dosage-form sweep of all estradiol products in Drugs@FDA returns zero pellet and zero implant entries. A payer says the same thing in plain English: BlueCross BlueShield of South Carolina, Medical Policy CAM 019 writes that "There are no FDA-approved, commercially available formulations of implantable estradiol pellets available in the United States."

Why are hormone pellets not recommended?

Four bodies have published on compounded hormones in a way that reaches pellets. Each one is quoted verbatim below, with its document and date, so you can check the wording at the source itself.

The mechanism behind all four positions is the same, and ACOG states it directly: the pellet is designed to dissolve rather than be removed. Every other route can be stopped. A cream gets washed off, a patch comes off, a pill gets skipped. A pellet delivering more hormone than intended keeps delivering it for the 3 to 6 months it takes to erode.

ACOG also quantifies the dose-accuracy problem for compounded hormones generally. Across 13custom-compounding pharmacies, it reports, "levels could be as much as 26% below label for estradiol and 31% above label for progesterone". That figure covers compounded preparations as a class rather than pellets specifically, and it is the reason the irreversibility matters: a route you cannot stop combined with a dose you cannot verify.

What is the downside of hormone pellets?

One study has compared compounded pellet therapy against FDA-approved hormone therapy in the same population, and it is the most citable evidence on this page. Jiang X, Bossert A, Parthasarathy KN, Leaman K, Minassian SS, Schnatz PF, Woodland MB published it in Menopause 2021;28(8):867-874. It covered 539 postmenopausal women, 384 on pellets and 155 on FDA-approved therapy. Authors reported no conflicts of interest.

Four women on pellets recorded estradiol above 1,000 pg/mL. Nine recorded total testosterone above 400 ng/dL.

Menopause 2021;28(8):867-874, PMID 33973545

Extrusion, infection, and what the technique does to the rate

Extrusion means the pellet works its way back out through the incision. Published rates span a factor of thirty across three studies, and the spread itself is the finding: the number tracks who is doing the procedure and how, more than it tracks the pellet.

The 2011 comparison is the useful one for a patient. Changing the insertion technique moved extrusion from 7.5% to 0.8% and infection from 5% to 1.2% in the same practice. The question to ask a clinic offering pellets is how many insertions the person holding the trocar has done, because that is the variable with the biggest measured effect.

One number you will not find here: a rate for surgically removing a pellet once it is in. No peer-reviewed removal rate exists, so we publish none. ACOG's statement that the pellet is not designed to be removed is the citable authority on the point.

The strongest published case for pellets

A page carrying only one side of this is an advocacy page. Jacobsen L, Fernandes DM, Nagel ML, Souza EL, Viana DPDC published narrative review in J Clin Med 2025;15(1):48 arguing the other way. No external funding, no declared conflicts. Its pharmacokinetic figures for subcutaneous estradiol:

Stable levels for 4 to 6 months. Markedly supraphysiological levels above 477 pg/mL occurred in about 3% in large cohorts. Its position on the safety record is that safety concerns “are mainly associated with excessive dosing, premature reimplantation, or lack of endometrial protection in women with a uterus”. It attributes the harm to how the procedure is practised rather than to the route itself. If that reading is right, better dosing discipline and mandatory endometrial protection would fix most of what the Menopause 2021 data picked up.

Set against it, a 2025 critical review reached the opposite conclusion on evidence quality: "The evidence supporting testosterone pellets in women is limited and of low quality, with methodological flaws and inconsistent findings. Most studies are observational, with few small randomized trials." Its evidence table includes a series of 297 women at a mean dose of 133.3 mg, which reported "Wide variation in serum levels besides identical dosing", along with 11.2% acne and 1% voice changes.

Scope note on that second paper, because it changes how much of it applies here: Brazilian, and substantially concerned with gestrinone and nestorone pellets, which are not in the US market. Only its testosterone and estradiol findings transfer. Rev Assoc Med Bras 2025;71(7):e20250121.

Where that leaves the reader: the case for pellets rests on pharmacokinetics and on the argument that harm comes from practice. The case against rests on outcomes measured in patients, on the irreversibility of the route, and on the absence of any FDA-approved product for the indication most people are buying it for.

How much does BioTE therapy cost?

Start with what does not exist. There is no national dataset for pellet pricing, no CMS schedule, no payer aggregate, no trade-body survey. Every figure in circulation is a clinic's own published number, self-reported and unaudited, including every figure on every page currently ranking for this question. Four clinic-published price pages, self-reported and unaudited.

Biote itself does not set the price. It certifies the practitioner, and the practitioner charges what the practitioner charges, which is why the spread below is as wide as it is for the same procedure.

Does insurance cover hormone pellets?

We can show you exactly one payer's answer, because exactly one payer publishes a policy specific enough to quote. BlueCross BlueShield of South Carolina maintains Medical Policy CAM 019, Implantable Hormone Pellets, last reviewed 2026-04-01. Its three operative lines:

• "Implanted estrogen (including estradiol) pellets are considered INVESTIGATIONAL"
• "Implantable testosterone pellets are considered INVESTIGATIONAL for the treatment of symptoms associated with menopause"
• "Bioidentical Hormone Replacement Implants are considered to be INVESTIGATIONAL, as they are not FDA-approved. Therefore, they are not a covered benefit."

The policy separates FDA-approved Testopel, for males with congenital or acquired androgen deficiency, from compounded pellets. That separation is the interesting part: the same document treats the FDA-approved product and the compounded product as different things, which is the distinction the marketing collapses.

One payer is one payer. This does not establish that no plan in the country covers pellets, and we are not saying it does. It shows what one carrier concluded, in writing, in April 2026. Read the policy. Broader coverage rules for hormone therapy are on our HRT insurance page.

Is BioTE a legit company?

biote Corp. trades on Nasdaq under BTMD, is incorporated in Delaware, is headquartered in Irving, TX, and files annual reports with the SEC. Everything in this section comes from its Form 10-K for the fiscal year ended 2025-12-31. That is the company describing itself under securities law, with the liability that carries.

So the honest answer to the question people type. Biote is a real, audited, publicly traded company doing what it says it does. The product its certified practitioners prescribe is a compounded drug that has not been through FDA approval, and the company states that itself on page 43 of its annual report.

biote Corp Form 10-K, fiscal year ended 2025-12-31, SEC EDGAR

What is better, testosterone injections or pellets?

No trial has compared the two routes head to head at a standard worth quoting, so anyone handing you a clean winner is guessing. Three things the record does support. The AUA guideline states, conditionally, that "Commercially manufactured testosterone products should be prescribed rather than compounded testosterone, when possible.". Injectable testosterone has multiple FDA-approved products behind it while the pellet route has one, approved in 1972 through the generic pathway for males only. And an injection schedule stops the day you stop it, where a pellet keeps releasing for months.

The same logic runs on the women's side. FDA-approved estradiol exists as a patch, gel, spray, pill, cream and vaginal preparation, all of them stoppable, all of them batch-tested to an approved specification. Our estradiol page prices every one of those forms against the platforms that dispense it, and our progesterone page covers the other half of a standard regimen for anyone with a uterus.

Platforms on our roster with an FDA-approved formulary

Score-sorted, compounded-only formularies excluded. The price column reads each provider's own disclosure, so a per-visit fee is labelled as one and never rewritten into a monthly number.

The cheapest all-in monthly price on an FDA-approved formulary across our roster is Alloy at $40/mo, medication included. Compare that against the clinic-published pellet range above before deciding what the procedure is buying you.

Where to go next: our full rankings for the score methodology, the verified price table if cost is the deciding factor, and the bioidentical HRT guide for the FDA-approved versus compounded distinction in full.

Sources

• Drugs@FDA, all products with dosage form PELLET (openFDA)
• Drugs@FDA, all estradiol products by dosage form (openFDA)
• TESTOPEL prescribing information, label effective 2025-07-17 (openFDA)
• U.S. Food and Drug Administration, Statement on improving adverse event reporting of compounded drugs to protect patients, 2019-09-09 (Internet Archive capture)
• ACOG, Clinical Consensus No. 6, Compounded Bioidentical Menopausal Hormone Therapy. Obstet Gynecol 2023;142(5):1266-1273. Replaces Committee Opinion No. 532 (2012). Endorsed by ASRM.
• The Menopause Society, 2022 Hormone Therapy Position Statement. Menopause 2022;29(7):767-794.
• Endocrine Society, Position Statement, Compounded Bioidentical Hormone Therapy. Endocrine Society position statement.
• National Academies (NASEM), The Clinical Utility of Compounded Bioidentical Hormone Therapy. NASEM 2020, DOI 10.17226/25791. Commissioned by the FDA.
• Jiang X, Bossert A, Parthasarathy KN, Leaman K, Minassian SS, Schnatz PF, Woodland MB. Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause 2021;28(8):867-874 (PMID 33973545)
• Cavender RK, Fairall M. J Sex Med 2009;6(11):3177-3192
• Conners W, Flinn K, Morgentaler A. J Sex Med 2011;8(12):3465-3470
• Kelleher S, Conway AJ, Handelsman DJ. Eur J Endocrinol 2002;146(4):513-518
• Jacobsen L, Fernandes DM, Nagel ML, Souza EL, Viana DPDC. Subcutaneous Estradiol Pellets as Hormone Therapy in Menopause. J Clin Med 2025;15(1):48 (PMID 41517302)
• Wender MCO et al. Compounded hormonal pellets: a critical review of current evidence and risks. Rev Assoc Med Bras 2025;71(7):e20250121
• AUA Testosterone Deficiency Guideline, 2018, validity confirmed 2024
• BlueCross BlueShield of South Carolina, Medical Policy CAM 019, Implantable Hormone Pellets, last reviewed 2026-04-01
• biote Corp, Form 10-K for the fiscal year ended 2025-12-31, SEC EDGAR (CIK 0001819253)
• Solid Wellness, published pellet pricing (clinic-published, unaudited)
• Cherry Heights Family Clinic, published pellet pricing (clinic-published, unaudited)
• Berman Women's Wellness, published pellet pricing (clinic-published, unaudited)
• Highland Longevity, published pellet pricing (clinic-published, unaudited)

This is general information, not medical advice. Hormone pellets are prescribed and implanted by a licensed clinician, and whether any hormone therapy fits your history is a decision for you and that clinician. Primary sources on this page were read and verified on 2026-08-15. Written and reviewed by Iacob Pastina. Corrections go to our editorial policy page.